

TREATMENT



Supervisory Board of the network

Deliverable D2.24

WP2

Training European Network:
Metabolic Dysfunctions associated
with Pharmacological Treatment of
Schizophrenia TREATMENT

Grant Agreement number: 721236



TREATMENT



DELIVERABLE FACTSHEET

Deliverable Number: D2.24

Deliverable Title: Supervisory Board of the network

WP Number: WP2

WP Title: Training: ETN Training

Lead Beneficiary: CSIC

Dissemination level: Public

Version: 1 Version

Date: 22/02/2017



TREATMENT



Disclaimer and acknowledgement

This project has received funding from the European Union's Horizon 2020 research and innovation Programme under the Marie Skłodowska-Curie Grant Agreement number 721236. This document has been prepared by TREATMENT partners.

Members

The Supervisory Board (SB) is composed of representatives of all beneficiaries and partner organizations and may also include any other stakeholders of relevance to the training Programme, including those from the non-academic sector. An Appropriate gender balance should be respected in the board's composition. It is also considered best practice to include a representative from among the recruited ESRs.

TREATMENT SB includes representatives of all beneficiaries and partners, three representatives ESRs and 5 members of the External Advisory Board (EAB) and will be headed by the consortium coordinators (Angela M. Valverde & María Monsalve, Agencia Estatal Consejo Superior de Investigaciones Científicas, CSIC).

The EAB will provide external supervision of ESRs activities. It is composed of 5 members that are internationally recognized



TREATMENT



experts in their field, and whose expertise covers all research and training aspects of the consortium.

The EAB will advise the Network how to ensure full coverage of training in the multiple skills required by industry and academia to predict drug induced metabolic dysfunctions. Focus will be on scientific excellence, leadership and transnational & inter-sectorial mobility, boosting ESRs ability to assimilate the individual components of the skills spectrum needed to oversee and in a goal-oriented manner direct the multi-sectorial process of life-long pharmacological disease management in general, but metabolic ADRs in particular.

Supervisory Board Members		
Beneficiaries		
1.- Agencia Estatal Consejo Superior de Investigaciones Científicas	CSIC	Ángela M. Valverde, María P. Monsalve, Santiago Lamas
2.- Uppsala University	UU	Jan Eriksson
3.- Centre for Neuroscience and Cell Biology	CNC	Eugenia Carvalho, John Jones
4.- Hebrew University of Jerusalem Israel	HUJ	Boaz Tirosh
5.-University of Ljubljana	UL	Irina Milisav
6.- Fundation Biomedical Research of Hospital de La Princesa	FIBHUP	Francisco Abad - Santos
7.- NIMGenetics, Genómica y Medicina, S.L	NIMG	Juan Cruz Cigudosa
8.- BNML – Behavioral & Molecular Lab Lda	BNML	Joao Bessa
9.- Cell Stress Discoveries Ltd	CSD	Afshin Samali
Partner Organisations		
1.- Centro de Investigación Biomédica en Red	CIBERSAM	Pilar López García
2.- Universitat de Lleida	ULL	Joaquin Ros
3.- ANAXOMICS Biotech S.L.	Anaxomics	Judith Farrés



TREATMENT



EAB Members		
1.- Hospital Universitario de Getafe		Locadio Rodríguez-Mañas*
2.- Children's Hospital Research Institute		Elisabet Borsheim**
3.- Bellvitge Biomedical Research Institute		Isabel Fabregat***
4.- Universidad Autónoma de Madrid		Manuela García López****
5.- Centro de Biología Molecular Severo Ochoa		Celso Arango*****

**Leocadio Rodríguez-Mañas, MD, PhD* (leocadio.rodriguez@salud.madrid.org) Head of the Geriatrics Unit, Hospital Universitario de Getafe, Madrid

***Elisabet Borsheim, MD, PhD* (EBorsheim@uams.edu) Associate Professor, Dept. of Pediatrics, UAMS; Senior Investigator, Arkansas Children's Nutrition Center; Investigator, Arkansas Children's Hospital Research Institute; Director, Energy Expenditure and Metabolism Program

****Isabel Fabregat, PhD* (ifabregat@idibell.cat) Senior Research Scientist. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

*****Manuela García López, PhD* (manuela.garcia@uam.es) Professor of Pharmacology (UAM) and Vicepresident of Instituto Teófilo Hernando for R&D of drugs, Madrid, Spain

***** *Celso Arango López, MD, PhD* (carango@hggm.es) Director of the CIBERSAM and Head of the Unit of Pediatric Psychiatry of the Hospital Gregorio Marañón, Madrid, Spain

Task

The SB will coordinate the training activities, oversee the Programme and ensure an adequate balance between scientific/technological and transferable skills training. This shall be achieved through personalized research projects and training, appropriate to the needs of each Marie Skłodowska-Curie Actions.

TREATMENT SB includes also non-academic members. Involvement of the non-academic sector in the SB aims to ensure that the skills acquired by researchers fulfil the needs of both academia and the non-academic sector and enhance the inter-sectoral employability of the researchers. The SB will also establish an active and continuous communication and exchange



TREATMENT



of best practice among the partners to maximize the benefits of the partnership.

If conflicts arise among WP leaders, supervisors, ESRs and partners, the SB will mediate and decide. The SB will hold meetings to gather information and discuss issues using telephone, Skype or other remote connection system. The SB will be in charge of dealing with Risk Management and Conflict of Interest issues, in those aspects directly affecting the ESRs.

The SB will meet annually for approval of annual plans for the project and for the supervision of ESRs and every six months to monitor the progress of the training Programme. The SB will make sure that the participating organizations will make available the committed resources. The SB will take actions to ensure the project progress as planned.

TREATMENT's governing structure, through the participation of all members in the SB, will guarantee a good representativeness of all the public and private interests. The newly recruited ESRs will be trained in the project management system in a devoted session of the kick-off meeting. This will provide all participants "a similar language", planning and reporting tools, and will also inform about the singularities of the European Grant Management, facilitating transparency and coordination of the network.

